The Hepatitis B surface antibody assay performed at Core recently received FDA approval to report quantitative results. In the past Hepatitis B surface antibody results were reported only as Reactive or Non-reactive along with the CDC guidelines indicating immunity status. Beginning April 6, 2010, Alverno Clinical Laboratories will change the reporting of Hepatitis B surface antibody from qualitative results to quantitative results.

According to CDC guidelines Hepatitis B surface antibody results equal to or greater than 10 mIU/mL indicate immunity¹. This antibody response may be due to successful immunization, past HBV infection or passively acquired antibody (transfusion). The CDC guidelines will appear on every report. The quantitative result will replace the Reactive or Non-reactive interpretation.

Only the reporting format will change not the test itself, therefore no changes are required by our clients or other IS systems. The specimen requirement, test code, billing code, CPT code and the turnaround time will not change.

Thank you for your continued support as we move forward to provide quality testing for our clients.


For further test information, please contact our client services department (800) 937-5521

Alverno Clinical Laboratories, LLC 2434 Interstate Plaza Dr. Hammond, Indiana 46324